Merck - 54 Year Stock Price History | MRK

Historical daily share price chart and data for Merck since 1970 adjusted for splits and dividends. The latest closing stock price for Merck as of December 03, 2024 is 101.85.
  • The all-time high Merck stock closing price was 132.10 on June 24, 2024.
  • The Merck 52-week high stock price is 134.63, which is 32.2% above the current share price.
  • The Merck 52-week low stock price is 94.48, which is 7.2% below the current share price.
  • The average Merck stock price for the last 52 weeks is 118.98.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Merck Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2024 118.7129 111.1202 132.0977 96.3100 101.8500 -4.79%
2023 104.5345 106.1050 113.7883 97.5950 106.9792 1.00%
2022 84.3474 71.1196 107.0406 68.0109 105.9236 49.38%
2021 70.2167 72.2881 82.9902 64.4396 70.9068 -2.92%
2020 70.9357 79.6598 79.6598 57.9254 73.0381 -7.21%
2019 70.1033 63.6924 79.4002 61.4427 78.7165 22.26%
2018 53.2049 45.9487 66.3749 43.8891 64.3834 40.00%
2017 49.9694 47.6926 53.6132 43.8403 45.9895 -1.47%
2016 44.8187 40.3100 51.1176 37.3221 46.6777 15.05%
2015 42.6490 42.5030 46.8432 36.8664 40.5712 -3.87%
2014 41.8095 35.6854 45.6424 35.6854 42.2057 16.95%
2013 32.7939 28.7391 36.0892 28.3984 36.0892 26.80%
2012 28.0707 25.5590 33.0181 24.8983 28.4610 13.13%
2011 22.1940 22.9678 25.2921 19.4248 25.1586 9.54%
2010 22.4254 22.6159 25.0724 19.6447 22.9678 2.86%
2009 17.6293 17.9669 23.2208 12.3649 22.3287 26.73%
2008 20.9030 31.8250 33.5890 13.4615 17.6192 -45.34%
2007 27.6871 23.6947 33.7111 23.1133 32.2355 37.36%
2006 20.2145 16.9373 24.6637 16.9373 23.4686 42.66%
2005 15.4210 15.3798 17.3920 13.1983 16.4512 4.04%
2004 20.1884 22.2933 23.2774 12.6189 15.8127 -27.76%
2003 23.9433 25.4085 27.9525 19.0753 21.8905 -11.35%
2002 23.2377 25.4155 27.5290 16.8068 24.6932 -1.26%
2001 29.8513 38.6839 38.6839 24.3140 25.0072 -35.79%
2000 30.4133 27.6493 39.4119 22.1590 38.9460 41.78%
1999 29.6883 30.1517 34.8928 24.7160 27.4695 -7.47%
1998 25.7175 21.3250 31.9431 20.3936 29.6887 41.32%
1997 18.5397 15.5425 21.2656 15.5425 21.0079 35.61%
1996 13.0881 12.2385 16.3104 10.9115 15.4919 23.92%
1995 9.3104 7.1266 12.7395 6.7775 12.5014 76.57%
1994 6.0694 6.3225 7.3123 5.1348 7.0802 14.82%
1993 6.1931 7.6392 7.6392 5.0712 6.1664 -18.35%
1992 8.3603 9.4678 9.6095 7.1214 7.5522 -20.29%
1991 6.7587 4.9950 9.4746 4.5903 9.4746 88.88%
1990 4.3517 4.2786 5.0162 3.6761 5.0162 18.95%
1989 3.7878 3.0411 4.3283 3.0411 4.2171 37.47%
1988 2.8685 2.8391 3.1398 2.5132 3.0677 12.05%
1987 2.9037 2.1764 3.7569 2.1764 2.7378 27.96%
1986 1.6514 1.1918 2.2368 1.1692 2.1396 80.83%
1985 0.9483 0.8043 1.1832 0.7806 1.1832 45.75%
1984 0.7654 0.7806 0.8377 0.6888 0.8118 4.00%
1983 0.7854 0.7255 0.9004 0.7082 0.7806 6.81%
1982 0.6639 0.7384 0.7578 0.5549 0.7308 -0.15%
1981 0.7507 0.7427 0.8842 0.6607 0.7319 0.00%
1980 0.6283 0.6110 0.7319 0.5074 0.7319 17.29%
1979 0.5831 0.5862 0.6380 0.5408 0.6240 6.85%
1978 0.4973 0.4631 0.5970 0.4157 0.5840 21.84%
1977 0.4850 0.5786 0.5786 0.4351 0.4793 -18.53%
1976 0.6177 0.6014 0.6942 0.5441 0.5883 -1.64%
1975 0.6432 0.5808 0.7384 0.5074 0.5981 4.33%
1974 0.6207 0.6942 0.7395 0.4232 0.5733 -17.79%
1973 0.7715 0.7816 0.8680 0.6715 0.6974 -9.39%
1972 0.6596 0.5409 0.7730 0.5409 0.7697 43.73%
1971 0.4578 0.4102 0.5646 0.4102 0.5355 25.26%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $254.507B $60.115B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $759.263B 78.64
Novo Nordisk (NVO) Denmark $487.660B 35.17
Johnson & Johnson (JNJ) United States $372.700B 15.12
AbbVie (ABBV) United States $321.213B 16.91
Novartis AG (NVS) Switzerland $214.211B 14.24
AstraZeneca (AZN) United Kingdom $207.865B 17.69
Pfizer (PFE) United States $146.322B 10.01
Sanofi (SNY) $121.714B 11.02
Innoviva (INVA) United States $1.197B 9.96